BioSilta Completes EUR 2.5 Million ($3.4 Million) Funding Round

Investment will be used to support commercial expansion in Europe and the USA

Cambridge, UK, 11th June 2014: BioSilta Ltd, a developer of advanced microbial growth systems, today announced that it has received EUR 2.5 million from Omega Funds (London) and existing investor Inveni Capital (Helsinki). The funding will be used to support commercial expansion through direct sales and marketing teams in Europe and the USA, and the establishment of distribution networks in other regions to increase sales of the Company’s EnPresso® product line. The investment will also be used to accelerate the introduction of new products in BioSilta’s pipeline.

(more…)

Read More

Medeia Therapeutics Ltd to participate in a new EU Project

Medeia Therapeutics announced today that European Commission has granted 3.4 million EUR to fund a new Marie Curie Initial Training Network called “nEUROinflammation”. In addition to Medeia 12 other partner organizations from industry and academia in 9 European countries will be investigating inflammatory processes in the brain with a common aim to improve therapeutic opportunities especially for stroke and multiple sclerosis. (more…)

Read More

Medtentia Helix Ring for Mitral Valve Repair Continues to Achieve All Objectives in Approval Study

Press release
Helsinki, Finland, July 31, 2013
Medtentia Helix Ring for Mitral Valve Repair Continues to Achieve All Objectives in Approval Study

Medtentia International Ltd Oy today announced that the surgeons at Helsinki University Hospital led by Prof Werkkala have successfully continued to recruit patients for the official second phase of the clinical approval study evaluating the safety and efficacy of the “Medtentia Helix Ring in Adults Undergoing Mitral Valve Repair Surgery”. (more…)

Read More

BioSilta introduces EnPresso B growth systems for bacterial cultures

Systems increase yields and improve functionality of recombinant proteins

BioSilta Oy, a developer of advanced microbial growth systems, today announced the commercial launch of the first products in its proprietary EnPresso® B range of reagent-based growth systems for bacterial cultures. Extensive results from independent labs around the world have confirmed that these new products typically increase protein yields by five to 100-fold and improve protein functionality when compared to results using conventional growth media. (more…)

Read More

Priaxon Enters Collaboration with GSK on Protein-Protein-Interactions

Munich, Germany – 07 January 2013. Priaxon, an emerging pharmaceutical company based in Germany, today announced a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions. Priaxon will provide its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigating the modulation of protein-protein interactions (PPIs). PPIs play an important role in many cell signaling pathways and cell-surface receptor-ligand interactions that become dysregulated in disease states. (more…)

Read More

Laurantis Pharma Completes Funding Round for Research Program

Tuesday, 04 September 2012 18:52

Laurantis Pharma Completes Funding Round for Research Program

(Boston, Mass., Turku, Finland / 4 September 2012) Laurantis Pharma today announced successful completion of a funding round, which raised € 5.64 million (US$7.02 million). A significant amount of the financing was secured from Broadview Ventures, Inc., which served as a catalyst for raising funds from Inveni Capital, Aloitusrahasto Vera, Helsinki University Funds, and Veritas.
The Broadview funding will support the first human trial for Lymfactin, which has potential to become the first treatment for breast cancer-associated lymphedema. Lymfactin uses an adenoviral vector to deliver vascular endothelial growth factor (VEGF-C) during transplantation of lymph nodes in order to avoid lymphedema. (more…)

Read More